PFE’s Xeljanz revenue trends
In 4Q17, in the US and in international markets, Pfizer’s (PFE) Xeljanz generated revenues of $340 million and $70 million, respectively, compared with $239 million and $40 million in 4Q16, reflecting a ~42% rise and a 78% rise on a YoY (year-over-year) basis.
In fiscal 2017, Xeljanz reported revenues of $1.3 billion, which represents a ~45% rise on a YoY basis. In 2017, in the US and in international markets, Xeljanz reported revenues of $1.1 billion and $212 million, respectively, compared with $805 million and $122 million in 2016, representing a ~41% rise and a ~75% rise, respectively, on a YoY basis.
In December 2017, the FDA (US Food and Drug Administration) approved Xeljanz 5 mg (milligrams) twice daily and Xeljanz XR (11 mg extended release, once daily) for the treatment of adult individuals with active psoriatic arthritis who showed an inadequate response or intolerance to other DMARDs (disease-modifying antirheumatic drugs).
The FDA’s approval of Xeljanz was based on the results of the phase-3 Opal clinical program, which consisted of two pivotal clinical trials, Opal broaden, Opal beyond, and the long-term extension trial Opal Balance.
In the Opal clinical program, Xeljanz demonstrated statistically significant progress in ACR20 (American College of Rheumatology – 20% improvement) and HAQ-DI (Health Assessment Questionnaire–Disability Index).
The FDA’s approval of Xeljanz for psoriatic arthritis is expected to further boost the drug’s sales growth.
In December 2017, Pfizer initiated a phase-3 clinical trial with Pfizer’s investigational Janus Kinase inhibitor PF-04965842 for the evaluation of its safety and efficacy in the treatment of individuals with moderate to severe atopic dermatitis.
Notably, Pfizer is actively strengthening its immunology portfolio for the long-term growth. Continue to the next part of this series for a closer look at the performance of Pfizer’s Peri-LOE products in 4Q17 and 2017.